| Document |
Document Title |
|
WO/2023/056368A1 |
Cyclic peptides capable of inhibiting Gonadotropin Regulated Testicular Helicase (GRTH) phosphorylation are provided. The cyclic peptides showed effective delivery into COS-1 and germ cells and a dose-dependent inhibitory effect on GRTH ...
|
|
WO/2023/051780A1 |
The present invention relates to an oral pharmaceutical composition. Specifically, the present invention relates to an oral pharmaceutical composition containing S-(+)-N,N-dimethyl-a-[2-(naphthyloxy)ethyl]benzylamine and (S)-2-(2-hydroxy...
|
|
WO/2023/053009A1 |
The present invention relates to pyridines and their use for increasing GBA activity and/or levels as well as treatment of GBA-related diseases, such as Parkinson's disease.
|
|
WO/2023/048152A1 |
The present invention provides: a compound having a serotonin 5-HT2A receptor antagonist and/or inverse agonist activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same. A compound represen...
|
|
WO/2023/047326A1 |
The object of the invention relates to an association of molecular oxygen and hyaluronic acid or salts thereof for use in the treatment of candidiasis, preferably recurrent candidiasis; and a kit for use in the treatment of symptoms asso...
|
|
WO/2023/046817A1 |
The invention provides novel heterocyclic compounds having the general formula (I), andpharmaceutically acceptable salts thereof, wherein R1 to R5 and X are as described herein. (I)Further provided are pharmaceutical compositions includi...
|
|
WO/2023/046877A1 |
The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including ...
|
|
WO/2023/040938A1 |
Provided is a method for regulating an ILK signaling pathway in a cell, comprising administering to a cell a mesenchymal stem cell exosome derived from mesenchymal stem cells, in particular derived from induced pluripotent stem cells. Al...
|
|
WO/2023/041375A1 |
The invention relates to an oral thin-film comprising at least one matrix layer, wherein the at least one matrix layer comprises: at least one polyvinyl alcohol having a low average molecular weight; and at least one polyvinyl alcohol ha...
|
|
WO/2023/042714A1 |
According to one aspect of the present invention, a method for detecting bacteria of the genus Fusobacterium in order to diagnose endometriosis includes a step for detecting bacteria of the genus Fusobacterium in a sample collected from ...
|
|
WO/2023/043171A1 |
The present invention relates to a composition for alleviating, preventing or treating premenstrual syndrome, comprising fermented Pueraria lobate, which is obtained by inoculating a Pueraria lobate extract with a Lactobacillus paracasei...
|
|
WO/2023/042214A1 |
The present invention relates to solid state forms of Gonadotropin-Releasing Hormone Receptor (GnRH) antagonist of Formula (I) and a pharmaceutically acceptable salt thereof, namely 1-(4-(l-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-...
|
|
WO/2023/043392A1 |
The present invention relates to the anti-hypertensive properties of the mad honey (Rhododendron honey) and its extracts, and the extracts of the parts of flowers, pollen, leaves, roots, and bark of the Rhododendrons, and the formulation...
|
|
WO/2023/038258A1 |
The present invention relates to a Lactobacillus gasseri LM1065 strain (KCCM13018P), and a composition, for alleviating premenstrual syndrome, comprising same. The Lactobacillus gasseri LM1065 strain (KCCM13018P) according to one impleme...
|
|
WO/2023/036177A1 |
Disclosed in the present invention are a thiophene ring compound, a preparation method therefor and an application thereof. The structure of the thiophene ring compound of the present invention is as shown in formula I. The compound of t...
|
|
WO/2023/038999A1 |
Methods of enhancing or improving fertility are disclosed. Methods of extending reproductive longevity are disclosed. Methods of increasing oocyte mitochondrial mass or preventing a decrease of oocyte mitochondrial mass are disclosed. Me...
|
|
WO/2023/037264A1 |
A contraceptive regimen that provides for a reduced level of estrogen. The contraceptive regimen can be used for the treatment of symptoms associated with endometriosis or fibroids.
|
|
WO/2023/038350A1 |
The purpose of the present application is to provide a composition for alleviating premenstrual syndrome, containing, as an active ingredient, mixed strains of a Lactobacillus gasseri LM1065 strain (KCCM13018P) and a Lactobacillus reuter...
|
|
WO/2023/030492A1 |
An EP4 antagonist represented by formula I, which specifically comprises a crystal form thereof, a pharmaceutically acceptable salt or crystal form thereof, a preparation method therefor, a composition containing same, and a medical use ...
|
|
WO/2023/031218A1 |
The present disclosure provides methods of detection and diagnosis of ectopic endometriosis. The disclosure further provides compositions, medicaments and methods for treating or preventing ectopic endometriosis.
|
|
WO/2023/030293A1 |
Provided is a crystallization process of a GnRH receptor antagonist. Specifically, provided is a crystallization process of a crystal form of a compound of formula (I).
|
|
WO/2023/026830A1 |
[Problem] To provide a method for producing extracellular particles usable for a vaccine for a swine infectious disease. [Solution] A method for producing extracellular particles that comprises: infecting swine cells, which can be infect...
|
|
WO/2023/027950A1 |
Compositions and methods for the reproductive management of sheep and goats are provided. More particularly, methods for stimulating follicular maturation and/or synchronizing ovulation in sheep and goats are provided. In some embodiment...
|
|
WO/2023/027553A1 |
The present invention relates to a composition for preventing, treating or ameliorating poor ovarian response syndrome, comprising an RGMc-derived protein. When the composition according to an aspect is used, this may induce the normal d...
|
|
WO/2023/020178A1 |
A use of a cell-free fat extract for preparing a composition or preparation. The composition or preparation is used for preventing and/or treating vaginal atrophy. The cell-free fat extract has an excellent therapeutic effect on vaginal ...
|
|
WO/2023/015180A1 |
Described are improved processes for the preparation of iodized fatty acid esters from free fatty acids via in-situ formation of hydroiodic acid using silane chemistry.
|
|
WO/2023/007088A1 |
The oral food supplement which makes it possible to protect against infertility caused by premature ovarian insufficiency or by endometriosis or by polycystic ovary syndrome (PCOS) in women, or by low sperm count in men, this being both ...
|
|
WO/2023/005973A1 |
A use of one or more lipid compounds in the delivery of nucleic acids, and a lipid nucleic acid mixture, pharmaceutical composition or kit comprising the lipid compounds and nucleic acids. The lipid compounds can promote the absorption, ...
|
|
WO/2022/165097A9 |
The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for tr...
|
|
WO/2023/009445A1 |
A pharmaceutical composition for use in the treatment of bacterial vaginosis, wherein said composition comprises a poloxamer, a stabilization polymer, and an active ingredient for treating the bacterial vaginosis, preferably clindamycin,...
|
|
WO/2023/007312A1 |
The present invention relates to a method for providing progestogen only contraception. The method consists of orally administering to a human subject desiring contraception a tablet consisting of about 0.115 mg to about 0.145 mg of levo...
|
|
WO/2023/005130A1 |
The present invention relates to the technical field of traditional Chinese medicine research for infertility, and in particular to a traditional Chinese medicine composition for treating the infertility, and a preparation method therefo...
|
|
WO/2023/003130A1 |
Provided is a pharmaceutical composition for the prevention or treatment of Asherman's syndrome or complications thereof, comprising mitochondria as an active ingredient. The pharmaceutical composition alleviates or treats endometrial ad...
|
|
WO/2023/001246A1 |
A method for preparing a polypeptide-containing fetal sheep zymolyte, mainly comprising the following steps: (1) taking a fetal sheep homogenate or dry powder, and adding water to and stirring same; (2) heating same to 50-60°C, adjustin...
|
|
WO/2023/000418A1 |
An altrenogest injection, a preparation method therefor, and an application thereof. Each 100 mL of the altrenogest injection comprises the following components: 0.1-35 g of altrenogest, 0.01-70 mL of polyethylene glycol, the remainder b...
|
|
WO/2023/286012A1 |
The present invention relates to a hydrolyzed collagen powder having specific characteristics, a. process for its preparation and uses thereof, in therapy and so on.
|
|
WO/2023/284466A1 |
Disclosed is the use of a cell-free fat extract for preparing a composition or a preparation. The composition or the preparation is used for preventing and/or treating ovarian insufficiency and/or complications thereof. The cell-free fat...
|
|
WO/2023/283578A1 |
In aspects, the present disclosure provides a method of treating or preventing premature ovarian insufficiency or polycystic ovary syndrome in a female mammal, the method comprising, consisting essentially of, or consisting of administer...
|
|
WO/2023/280937A1 |
The present invention relates to the use of lactic acid and/or lactic acid salts for treating and/or preventing vaginal symptoms, caused by a lack of oestrogen, of genitourinary syndrome of menopause, postmenopausal atrophic vaginitis, s...
|
|
WO/2023/282145A1 |
Provided is a composition for preventing or treating tissue aging which contains an S-adenosylmethionine synthase inhibitor. Also provided is a method for screening an anti-aging substance, the method comprising (1) a step for culturing ...
|
|
WO/2023/280765A1 |
The present invention relates to the choline salt (cholinate) of 2-(1-cyclobutyl-1H- pyrazol-4-yl)-5-[([1-[2-fluoro-4-(trifluoromethyl)- phenyl]cyclopropyl}carbonyl)amino]benzoic acid. In particular, the invention relates to the compound...
|
|
WO/2023/280309A1 |
The present disclosure relates to salt types of a tricyclic tetrahydro isoquinoline derivative. Specifically, the present disclosure relates to different salt types of a compound as represented by formula (I) and a preparation method the...
|
|
WO/2023/280243A1 |
Provided are miR-339 capable of activating a breast cancer-related gene, an miR-339-enhancer-target gene network activation model, and applications thereof. The locus of the miR-339 coincides with the histone modification marker H3K4me1o...
|
|
WO/2023/281430A1 |
The present invention relates to a complex between at least one lactoferrin and/or a hydrolyzate thereof with at least one pullulan, and a composition comprising said complex and at least one physiologically acceptable excipient, for ora...
|
|
WO/2023/272407A1 |
The present invention relates to the use of a combination of estretol (E4) and progesterone (P4) to prepare a medicine that is useful in the treatment of endometriosis. The medicine of the invention does not lower progesterone-receptor (...
|
|
WO/2023/272376A1 |
Migration of human peripheral leukocytes in response to chemotactic factors during pregnancy. The methods include determining the likelihood of a pregnant subject undergoing delivery within about 7 days by obtaining peripheral leukocytes...
|
|
WO/2023/276861A1 |
The present invention improves the sperm finding of mammalian animals, and in particular, male infertility patients. This composition for oral ingestion, which contains ergothioneine as an active component, is administered orally to a ...
|
|
WO/2022/247920A9 |
The present invention relates to a quinolinamine compound, a preparation method therefor and an application thereof in pharmaceuticals. Specifically, the present invention relates to a quinolinamine compound as represented by general for...
|
|
WO/2023/275088A1 |
A selective estrogen receptor modulator and/or an aromatase inhibitor (A) for use in a method of preventing or treating gynecomastia and/or mastalgia, wherein said method comprises administering said selective estrogen receptor modulator...
|
|
WO/2023/275132A1 |
The present invention relates to the field of medicine, in particular to internal and aesthetic regenerative medicine. More specifically, the present invention relates to a composition suitable for use as a transport medium for adipose t...
|
